Highlights of weekly biotech stock moves

Alimera Sciences Inc. (NASDAQ:ALIM) lost $5.41 (73%) to $1.96 on Friday after FDA asked for two additional clinical trials before it can approve Iluvien to treat diabetic macular edema (DME). Alimera has rights to the injectable insert delivering fluocinolone acetonide from pSivida Corp. (NASDAQ:PSDV; ASX:PVA), which fell $1.90 (48%) to $2.03 on NASDAQ on Friday. The announcement came after market close in Australia.

For the week, Alimera was off $5.35 (73%), while pSivida was off $2.12 (51%) on NASDAQ and off A$0.25 to A$4.10 in Australia...